To create digital tools to support young adult cancer survivors completing active treatment and transitioning into survivorship care.

This study will evaluate the use of MMUD PBSC in adults and explore the safety and efficacy of MMUD BM in pediatric recipients with hematological malignancies who may lack other donor options.

The purpose of this study is to create a registry that will collect clinical data from participants attending UNC Hospitals who may present with metastatic cancer and are evaluated to receive radiation therapy. We hope to create a registry that future studies can pull from to study the impacts of radiation therapy on patient cancer outcomes.

The main purpose of this clinical research study is to assess the safety, tolerability, efficacy (the ability of the study drug to produce the desired anti cancer effect), PK] and PD of GHF009X2101 the study drug in patients with relapsed or refractory hematologic malignancies including AML, CLL, SLL or other lymphomas [including other leukemia].

Cancer is the leading cause of death in the Hispanic population in the U.S. Our study focuses on collecting information to build a cancer registry from a diverse Hispanic population to identify specific cultural and demographic details that will allow us to determine which attribute carries a higher risk of a poor outcome. We will also be utilizing a set of questionnaires and surveys that evaluate the health and functionality of older adults thoroughly and efficiently. These surveys provide a wealth of prognostic data and have been shown to detect deficits even in younger patients. Although the information we hope to collect is of considerable value, we must first examine whether our approach to consenting patients and having them complete these questionnaires is feasible. We anticipate that the findings from our study will provide valuable insights on Hispanic adults with cancer as a unique and growing patient population in the U.S.

The primary objective of the current study is to assess cancer patient perceived barriers to adherence to oral cancer medications. The results of this survey will aid clinicians in identifying targeted priorities in future programs aimed at improving adherence in patients taking oral cancer medications.

No guidelines or interventions for patients and their family caregivers exist to support patient adherence to a new medication (venetoclax) and their quality of life. Our research team seeks to understand the real experience and care needs of patients and their family caregivers with the new AML treatment. With the information we learn from this study, we will be able to develop an effective support program for patients with AML and their family caregivers to manage their symptoms at home and improve their quality of life.

The purpose of this study is to test the safety of the two study drugs, venetoclax and selinexor, and to find the highest dose of venetoclax and selinexor that can be given safely when it is combined with chemotherapy drugs (cytarabine or cytarabine and fludarabine). This study tests different doses of venetoclax and selinexor to see which dose is safer in children with leukemia.

Cancer caregivers experience high levels of stress related to the caregiving role, particularly for rural caregivers. The purpose of this study is to assess the acceptability and preliminary effect of enCompass Carolina, a social support program for caregivers of rural-dwelling patients with cancer.

The expected outcome of this proposal is a novel care pathway delivered by pharmacists to improve side effects during oral chemotherapy for patients, a known barrier to adherence, and ultimately to prevent progression and early mortality. Our long-term goal for P3OC is to develop and test new dashboard features to optimize pharmacy care, meet future needs for value-based payment models, and improve patient outcomes.